Acute promyelocytic leukemia: What is the new standard of care?

Blood Reviews

Volumn 28, Issue 5, 2014, Pages 205-212

  Watts, Justin M ^a   Tallman, Martin S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute promyelocytic leukemia; All trans retinoic acid (ATRA); Arsenic trioxide (ATO); Coagulopathy; Differentiation syndrome; Early death

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; GEMTUZUMAB OZOGAMICIN; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID;

ANOREXIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD CLOTTING DISORDER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CHEILITIS; DISEASE FREE SURVIVAL; DRUG TREATMENT FAILURE; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FATIGUE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MAINTENANCE CHEMOTHERAPY; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QT PROLONGATION; REVIEW; SURVIVAL RATE; COMPLICATION; HEALTH CARE QUALITY; LEUKEMIA, PROMYELOCYTIC, ACUTE; MORTALITY;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; STANDARD OF CARE;

EID: 84906933580     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.07.001     Document Type: Review

References (92)

1. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. Proposals for the classification of the acute leukaemias: French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
2. Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A., Gralnick H.R., et al. A variant form of hypergranular promyelocytic leukaemia (M3). Br J Haematol 1980, 44:169-170.
3. Tallman M.S., Kwaan H.C. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992, 79:543-553.
4. Rowley J.D., Golomb H.M., Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1997, 1:549-550.
5. Grignani F., Ferrucci P.F., Testa U., Talamo G., Fagioli M., Alcalay M., et al. The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 1993, 74:423-431.
6. Tallman M.S., Altman J.K. Curative strategies in acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program 2008, 391-399.
7. Mistry A.R., Felix C.A., Whitmarsh R.J., Mason A., Reiter A., Cassinat B., et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005, 352:1529-1538.
8. Mays A.N., Osheroff N., Xiao Y., Wiemels J.L., Felix C.A., Byl J.A., et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood 2010, 115:326-330.
9. Beaumont M., Sanz M., Carli P.M., Maloisel F., Thomas X., Detourmignies L., et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003, 21:2123-2137.
10. Kolade V.O., Bosinski T.J., Ruffy E.L. Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease. Pharmacotherapy 2005, 25:1017-1020.
11. Grudeva-Popova J., Yaneva M., Zisov K., Ananoshtev N. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON 2007, 12:129.
12. Duffield A.S., Aoki J., Levis M., Cowan K., Gocke C.D., Burns K.H., et al. Clinical and pathologic features of secondary acute promyelocytic leukemia. Am J Clin Pathol 2012, 137:395-402.
13. Cunningham I., Gee T.S., Reich L.M., Kempin S.J., Naval A.N., Clarkson B.D. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989, 73:1116-1122.
14. Rodeghiero F., Avvisati G., Castaman G., Barbui T., Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 1990, 75:2112-2117.
15. Fenaux P., Degos L. Treatment of acute promyelocytic leukemia with all-trans retinoic acid. Leuk Res 1991, 15:655-657.
16. Head D.R., Kopecky K.J., Willman C., Appelbaum F.R. Treatment outcome with chemotherapy in acute promyelocytic leukemia: the Southwest Oncology Group (SWOG) Experience. Leukemia 1994, 8(Suppl. 2):S38-S41.
17. Iland H.J., Bradstock K., Supple S.G., Catalano A., Collins M., Hertzberg M., et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood 2012, 120:1570-1580.
18. Lo-Coco F., Avvisati G., Vignetti M., Thiede C., Orlando S.M., Iacobelli S., et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 2013, 369:111-121.
19. Huang M.E., Ye Y.C., Chen S.R., Chai J.R., Lu J.X., Zhoa L., et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
20. Castaigne S., Chomienne C., Daniel M.T., Ballerini P., Berger R., Fenaux P., et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76:1704-1709.
21. Chen Z.X., Xue Y.Q., Zhang R., Tao R.F., Xia X.M., Li C., et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991, 78:1413-1419.
22. Warrell R.P., Frankel S.R., Miller W.H., Scheinberg D.A., Itri L.M., Hittelman W.N., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991, 324:1385-1393.
23. Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., et al. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases. Blood 1992, 80:2176-2181.
24. Fenaux P., Le Deley M.C., Castaigne S., Archimbaud E., Chomienne C., Link H., et al. Effect of all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood 1993, 82:3241-3249.
25. Vahdat L., Maslak P., Miller W.H., Eardley A., Heller G., Scheinberg D.A., et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PML/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. Blood 1994, 84:3843-3849.
26. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
27. De Botton S., Dombret H., Sanz M., Miguel J.S., Caillot D., Zittoun R., et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1998, 92:2712-2718.
28. Tallman M.S., Andersen J.W., Schiffer C.A., Appelbaum F.R., Feusner J.H., Ogden A., et al. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000, 95:90-95.
29. Fenaux P., Chastang C., Chevret S., Sanz M., Dombret H., Archimbaud E., et al. A randomized comparison of all-trans retinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 1999, 94:1192-1200.
30. Avvisati G., Lo Coco F., Diverio D., Falda M., Ferrara F., Lazzarino M., et al. AIDA (all-trans retinoic acid+idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne Dell'adulto (GIMEMA) pilot study. Blood 1996, 88:1390-1398.
31. Sanz M.A., Martín G., Rayón C., Esteve J., González M., Díaz-Mediavilla J., et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA Group. Blood 1999, 94:3015-3021.
32. Sanz M.A., Grimwade D., Tallman M.S., Lowenberg B., Fenaux P., Estey E.H., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113:1875-1891.
33. Berman E., Little C., Kher U., et al. Prognostic analysis of patients with acute promyelocytic leukemia [abstract]. Blood 1991, 78(Suppl. 1):43A.
34. Avvisati G., Mandelli F., Petti M.C., Vegna M.L., Spadea A., Liso V., et al. Idarubicin (4-demethoxydaunorubicin) as single agent for remission induction of previously untreated acute promyelocytic leukemia: a pilot study of the Italian cooperative group GIMEMA. Eur J Haematol 1990, 44:257-260.
35. Burnett A.K., Hills R.K., Grimwade D., Goldstone A.H., Hunter A., Milligan D., et al. Idarubicin and ATRA is as effective as MRC chemotherapy in patients with acute promyelocytic leukemia with lower toxicity and resource usage: preliminary results of the MRC AML15 Trial. Blood 2007, 110:589. [ASH Annual Meeting Abstracts].
36. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
37. Niu C., Yan H., Yu T., Sun H.P., Liu J.X., Li X.S., et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
38. Soignet S.L., Frankel S.R., Douer D., Tallman M.S., Kantarjian H., Calleja E., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
39. Ghavamzadeh A., Alimoghaddam K., Ghaffari S.H., Rostami S., Jahani M., Hosseini R., et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Ann Oncol 2006, 17:131-134.
40. Mathews V., George B., Lakshmi K.M., Viswabandya A., Bajel A., Balasubramanian P., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006, 107:2627-2632.
41. Giannì M., Koken M.H., Chelbi-Alix M.K., Benoit G., Lanotte M., Chen Z., et al. Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 1998, 91:4300-4310.
42. Zheng P.Z., Wang K.K., Zhang Q.Y. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 2005, 102:7653-7658.
43. Shen Z.X., Shi Z.Z., Fang J., et al. All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2004, 101:5328-5335.
44. Hu J., Liu Y.F., Wu C.F., et al. Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 2009, 106:3342-3347.
45. Estey E., Garcia-Manero G., Ferrajoli A., et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood 2006, 107:3469-3473.
46. Ravandi F., Estey E.H., Cortes J.E., et al. Phase II study of all-trans retinoic acid (ATRA), arsenic trioxide (ATO), with or without gemtuzumab ozogamicin (GO) for the frontline therapy of patients with acute promyelocytic leukemia (APL). Blood 2010, 116:1080. [ASH Annual Meeting Abstracts].
47. Lou Y., Qian W., Meng H., et al. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia. Leuk Res 2013, 37:37-42.
48. Knipp S., Gattermann N., Schapira M., et al. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Leuk Res 2007, 31:1585-1587.
49. Mandelli F., Diverio D., Avvisati G., et al. Molecular remission in PML/RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Gruppo Italiano-Malattie Ematologiche Maligne Dell'adulto and Associazione Italiana Di Ematologia Ed Oncologia Pediatrica Cooperative Groups. Blood 1997, 90:1014-1021.
50. Sanz M.A., Lo-Coco F., Martin G., et al. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1253.
51. Sanz M.A., Martin G., Gonzalez M., et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 2004, 103:1237-1243.
52. Sanz M.A., Montesinos P., Rayon C., et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood 2010, 115:5137-5146.
53. Lo-Coco F., Avvisati G., Vignetti M., et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61years: results of the AIDA-2000 trial of the GIMEMA group. Blood 2010, 116:3171-3179.
54. Gore S.D., Gojo I., Sekeres M.A., et al. Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia. J Clin Oncol 2010, 28:1047-1053.
55. Powell B.L., Moser B., Stock W., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood 2010, 116:3751-3757.
56. Ravandi F., Estey E., Jones D., et al. Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol 2009, 27:504-510.
57. Mathews V., George B., Chendamarai E., et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: long-term follow-up data. J Clin Oncol 2010, 28:3866-3871.
58. Tallman M.S., Andersen J.W., Schiffer C.A., et al. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood 2002, 100:4298-4302.
59. Ades L., Guerci A., Raffoux E., et al. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group Experience. Blood 2010, 115:1690-1696.
60. Coutre S.E., Othus M., Powell B., et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol Feb 14 2014, [Epub ahead of print]. 10.1111/bjh.12775.
61. Au W.Y., Lie A.K., Chim C.S., et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia. Ann Oncol 2003, 14:752-757.
62. Lazo G., Kantarjian H., Estey E., Thomas D., O'Brien S., Cortes J. Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson Experience. Cancer 2003, 97:2218-2224.
63. Raffoux E., Rousselot P., Poupon J., et al. Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 2003, 21:2326-2334.
64. Shigeno K., Naito K., Sahara N., et al. Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies. Int J Hematol 2005, 82:224-229.
65. Ding W., Li Y.P., Nobile L.M., et al. Leukemic cellular retinoic acid resistance and missense mutations in PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 1998, 92:1172-1183.
66. Thirugnanam R., George B., Chendamarai E., et al. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen. Biol Blood Marrow Transplant 2009, 15:1479-1484.
67. Meloni G., Diverio D., Vignetti M., et al. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RAR alpha fusion gene. Blood 1997, 90:1321-1325.
68. Kishore B., Stewart A., Jovanovic J., Craddock C., Grimwade D. Arsenic trioxide and stem cell transplantation is an effective salvage therapy in patients with relapsed APL [abstract]. Br J Haematol 2010, 149(Suppl. 1):22.
69. Lengfelder E., Lo-Coco F., Ades L., et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: updated results of the European Registry of Relapsed APL (PROMYSE). Blood 2013, 122:1406. [ASH Annual Meeting Abstracts].
70. Lo-Coco F., Diverio D., Falini B., Biondi A., Nervi C., Pelicci P.G. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 1999, 94:12-22.
71. Grimwade D., Lo-Coco F. Acute promyelocytic leukemia: a model for the role of molecular diagnosis and residual disease monitoring in directing treatment approach in acute myeloid leukemia. Leukemia 2002, 16:1959-1973.
72. Grimwade D., Jovanovic J.V., Hills R.K., et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009, 27:3650-3658.
73. Esteve J., Escoda L., Martin G., et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007, 21:446-452.
74. Asou N., Adachi K., Tamura J., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998, 16:78-85.
75. Alizadeh A.A., McClellan J.S., Gotlib J.R., et al. Early mortality in acute promyelocytic leukemia may be higher than previously reported. Blood 2009, 114:1015. [ASH Annual Meeting Abstracts].
76. Derolf A.R., Kristinsson S.Y., Andersson T.M., Landgren O., Dickman P.W., Bjorkholm M. Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009, 113:3666-3672.
77. Micol J., Raffoux E., Boissel N., et al. Do early events excluding patients with acute promyelocytic leukemia (APL) from trial enrollment modify treatment result evaluation? Real-life management of 100 patients referred to the University Hospital Saint-Louis between 2000 and 2010. Blood 2010, 116:1083. [ASH Annual Meeting Abstracts].
78. Park J., Qiao B., Panageas K.S., et al. Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. Blood 2011, 118:1248-1254.
79. Altman J.K., Rademaker A., Cull E., et al. Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. Leuk Res 2013, 37:1004-1009.
80. De La Serna J., Montesinos P., Vellenga E., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111:3395-3402.
81. Lehmann S., Ravn A., Carlsson L., et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia 2011, 25:1128-1134.
82. Tallman M.S., Brenner B., Serna Jde L., et al. Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res 2005, 29:347-351.
83. Chang H., Kuo M.C., Shih L.Y., et al. Clinical bleeding events and laboratory coagulation profiles in acute promyelocytic leukemia. Eur J Haematol 2012, 88:321-328.
84. Di Bona E., Avvisati G., Castaman G., et al. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia. Br J Haematol 2000, 108:689-695.
85. Breccia M., Latagliata R., Cannella L., Minotti C., Meloni G., Lo-Coco F. Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation. Haematologica 2010, 95:853-854.
86. Visani G., Gugliotta L., Tosi P., et al. All-trans retinoic acid significantly reduces the incidence of early hemorrhagic death during induction therapy of acute promyelocytic leukemia. Eur J Haematol 2000, 64:139-144.
87. Jurcic J.G., Soignet S.L., Maslak A.P. Diagnosis and treatment of acute promyelocytic leukemia. Curr Oncol Rep 2007, 9:337-344.
88. Frankel S.R., Eardley A., Lauwers G., Weiss M., Warrell R.P. The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 1992, 117:292-296.
89. Wiley J.S., Firkin F.C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia. Australian Leukaemia Study Group. Leukemia 1995, 9:774-778.
90. Di Veroli A., Ramadan S.M., Divona M., et al. Molecular remission in advanced acute promyelocytic leukaemia after treatment with the oral synthetic retinoid tamibarotene. Br J Haematol 2010, 151:99-101.
91. Au W., Kumana C.R., Kou M., et al. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia. Blood 2003, 102:407-408.
92. Au W., Kumana C.R., Lee H.K., et al. Oral arsenic trioxide-based therapy maintenance regimens for first complete remission of acute promyelocytic leukemia: a 10-year follow-up study. Blood 2001, 118:6535-6543.